Skip to main content
Premium Trial:

Request an Annual Quote

Cetek Raises $10M in VC Financing

NEW YORK, Jan. 5 (GenomeWeb News) - Cetek raised $10 million from investors to advance its drug-discovery platform, the company said earlier this week.

 

Participating investors include Argonaut Private Equity, Ventry Industries, Gainesborough Investments, James L. Waters, and Stata Ventures. They are all current Cetek investors.

 

Cetek approaches drug discovery using high throughput capillary electrophoresis screening technology and chemical biology-focused drug source. The company said it uses its technologies through service agreements and collaborations.

 

The Marlborough, Mass-based company also announced a scientific advisory board. The chairman of the board is Cetek founder Barry L. Karger. Other members include K. Frank Austen from Harvard Medical School, James D. Griffin from Harvard Medical School, Charles L. Cooney, from the MIT Program on the Pharmaceutical Industry, and Martin S. Hirsch from Harvard School of Public Health; and Infectious Disease Service at the Massachusetts General Hospital.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.